- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03442322
Optimizing Care for Patients With Dementia
Optimizing Care for Patients With Dementia: A Comparison of Two Non-pharmacological Treatment Approaches
Of the 1.4 million nursing home (NH) residents in long term care facilities, more than half have Alzheimer's disease or dementia. Due to changes in their familiar daily routines, difficulty expressing their thoughts or asking for what they need, and overstimulation (such as noise) or under stimulation (such as lack of activity), individuals with dementia often display disruptive behaviors like resisting help or continually repeating the same phrases. Medications are often prescribed to reduce agitation and aggressive behavior; however, these medications may not be effective and can have a negative impact on the individual. Therefore, families and other stakeholders strongly advocate the use of other types of approaches that focus on minimizing the cause of the behavior. Two facility-based methodologies include the transdisciplinary approach for integrated dementia care, which combines the expertise of all NH staff, who work together to build a common language and approach for each resident, and the multidisciplinary approach for problem-based dementia care, in which each staff member conducts individual assessments and makes discipline-specific recommendations. While prior research suggests that both of these facility-based approaches are useful, the circumstances under which each approach is most effective are not clear. This project will prospectively randomize 80 nursing homes to one of the two treatment arms to compare the effect of the transdisciplinary approach versus the multidisciplinary approach.
This study will examine the difference between the two comparators with respect to facility rates of medications dispensed to residents with dementia, leading to enhanced quality of life for the resident.
This project is important because it will address a key clinical dilemma NH staff face as they strive to optimize the use of alternative approaches to reduce disruptive behaviors in residents with dementia. Transforming the quality of dementia care in NHs and enhancing the quality of life of residents with dementia are high priorities for families and other advocates.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- University of Pittsburgh
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Eligible nursing home facilities will
- lack any existing dementia program targeting reduction of off-label psychotropic medication use
- each serve >60 long-term care residents with Alzheimer's or dementia
- meet Center for Medicare & Medicaid Services' minimum requirements for NHs (e.g., meeting the mandated number of hours of staff training on dementia care, performing regularly scheduled resident assessments).
Exclusion Criteria:
Facilities will be excluded if they have
- less than 60 long-stay residents
- an existing formal dementia care program in place
- an off-label psychotropic medication reduction program
- is located in a state that requires more than the Center for Medicare & Medicaid Services' minimum for staff training requirements on the topic of dementia care
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: transdisciplinary approach
The transdisciplinary approach that is integrated across disciplines and provides core training for all providers, staff members, and stakeholders, using a common language to address care concerns and support continuity and sustainability
|
This approach is integrated across disciplines and provides core training for all providers, staff members, and stakeholders, using a common language to address care concerns and support continuity and sustainability;
|
|
Active Comparator: multidisciplinary approach
The multidisciplinary approach that is problem-based and draws on the expertise of individual healthcare providers (e.g., occupational therapy) to address care concerns.
|
This is a problem-based approach that draws on the expertise of individual healthcare providers (e.g., occupational therapy) to address care concerns.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dispensing of Psychotropic Medications
Time Frame: 6-month period (months 1-6)
|
Percentage of nursing home residents with dementia who received one or more antipsychotic medication over Months 1-6 of Intervention.
|
6-month period (months 1-6)
|
|
Dispensing of Psychotropic Medications
Time Frame: 12-month period (months 7-12)
|
Percentage of nursing home residents with dementia who received one or more antipsychotic medication over Months 7-12 of Intervention.
|
12-month period (months 7-12)
|
|
Dispensing of Psychotropic Medications
Time Frame: 18-month period (months 13-18)
|
Percentage of nursing home residents with dementia who received one or more antipsychotic medication over Months 13-18 of Intervention.
|
18-month period (months 13-18)
|
|
Behavioral Symptoms
Time Frame: 6-month period (months 1-6)
|
Percentage of nursing home residents with dementia who had behavioral symptoms over Months 1-6 of Intervention.
|
6-month period (months 1-6)
|
|
Behavioral Symptoms
Time Frame: 12-month period (months 7-12)
|
Percentage of nursing home residents with dementia who had behavioral symptoms over Months 7-12 of Intervention.
|
12-month period (months 7-12)
|
|
Behavioral Symptoms
Time Frame: 18-month period (months 13-18)
|
Percentage of nursing home residents with dementia who had behavioral symptoms over Months 13-18 of Intervention.
|
18-month period (months 13-18)
|
|
Wandering
Time Frame: 6-month period (months 1-6)
|
Percentage of nursing home residents with dementia who had wandering over Months 1-6 of Intervention.
|
6-month period (months 1-6)
|
|
Wandering
Time Frame: 12-month period (months 7-12)
|
Percentage of nursing home residents with dementia who had wandering over Months 7-12 of Intervention.
|
12-month period (months 7-12)
|
|
Wandering
Time Frame: 18-month period (months 13-18)
|
Percentage of nursing home residents with dementia who had wandering over Months 13-18 of Intervention.
|
18-month period (months 13-18)
|
|
Rejection of Care
Time Frame: 6-month period (months 1-6)
|
Percentage of nursing home residents with dementia who had rejection of care over Months 1-6 of Intervention.
|
6-month period (months 1-6)
|
|
Rejection of Care
Time Frame: 12-month period (months 7-12)
|
Percentage of nursing home residents with dementia who had rejection of care over Months 7-12 of Intervention.
|
12-month period (months 7-12)
|
|
Rejection of Care
Time Frame: 18-month period (months 13-18)
|
Percentage of nursing home residents with dementia who had rejection of care over Months 13-18 of Intervention.
|
18-month period (months 13-18)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Unintended Weight Loss
Time Frame: 6-month period (months 1-6)
|
Percentage of nursing home residents with dementia who had unintended weight loss over Months 1-6 of Intervention.
|
6-month period (months 1-6)
|
|
Unintended Weight Loss
Time Frame: 12-month period (months 7-12)
|
Percentage of nursing home residents with dementia who had unintended weight loss over Months 7-12 of Intervention.
|
12-month period (months 7-12)
|
|
Unintended Weight Loss
Time Frame: 18-month period (months 13-18)
|
Percentage of nursing home residents with dementia who had unintended weight loss over Months 13-18 of Intervention.
|
18-month period (months 13-18)
|
|
Falls
Time Frame: 6-month period (months 1-6)
|
Percent of nursing home residents with dementia who had falls over Months 1-6 of Intervention.
|
6-month period (months 1-6)
|
|
Falls
Time Frame: 12-month period (months 7-12)
|
Percent of nursing home residents with dementia who had falls over Months 7-12 of Intervention.
|
12-month period (months 7-12)
|
|
Falls
Time Frame: 18-month period (months 13-18)
|
Percent of nursing home residents with dementia who had falls over Months 13-18 of Intervention.
|
18-month period (months 13-18)
|
|
Depressive Symptoms
Time Frame: 6-month period (months 1-6)
|
Percent of nursing home residents with dementia who had depressive symptoms over Months 1-6 of Intervention
|
6-month period (months 1-6)
|
|
Depressive Symptoms
Time Frame: 12-month period (months 7-12)
|
Percent of nursing home residents with dementia who had depressive symptoms over Months 7-12 of Intervention.
|
12-month period (months 7-12)
|
|
Depressive Symptoms
Time Frame: 18-month period (months 13-18)
|
Percent of nursing home residents with dementia who had depressive symptoms over Months 13-18 of Intervention.
|
18-month period (months 13-18)
|
|
Physical Restraints Use
Time Frame: 6-month period (months 1-6)
|
Percent of nursing home residents with dementia who had physical restraint use over Months 1-6 of Intervention.
|
6-month period (months 1-6)
|
|
Physical Restraints Use
Time Frame: 12-month period (months 7-12)
|
Percent of nursing home residents with dementia who had physical restraint use over Months 7-12 of Intervention.
|
12-month period (months 7-12)
|
|
Physical Restraints Use
Time Frame: 18-month period (months 13-18)
|
Percent of nursing home residents with dementia who had physical restraint use over Months 13-18 of Intervention.
|
18-month period (months 13-18)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Natalie E Leland, PhD, University of Pittsburgh
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY19090117
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeWithdrawnAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.Active, not recruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
Stanford UniversityNot yet recruitingMCI With Increased Risk for Alzheimer Disease | Alzheimer s DiseaseUnited States
-
University of California, Los AngelesRecruitingAlzheimer Disease | Dementia Alzheimer Type | Alzheimer&Amp;#39;s Disease (AD) | Alzheimer&Amp;Amp;#39;s Disease | Mild Alzheimer&Amp;Amp;#39;s Disease | Moderate Alzheimer&Amp;Amp;#39;s Disease | Alzheimer&Amp;#39;s DementiaUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Heinrich-Heine University, DuesseldorfNot yet recruitingEarly Onset Alzheimer Disease | Alzheimer Disease (AD)Germany
-
Johns Hopkins UniversityNational Institutes of Health (NIH)Not yet recruiting
-
Xuanwu Hospital, BeijingEnrolling by invitation
-
Beijing Tiantan HospitalNot yet recruiting
-
Danyang Huichuang Medical Equipment Co., Ltd.RecruitingAlzheimer s DiseaseChina
Clinical Trials on transdisciplinary approach
-
Fortaleza UniversityCompleted
-
Massachusetts General HospitalNational Institute on Aging (NIA)Completed
-
Nemours Children's ClinicAlbert Einstein College of Medicine; Juvenile Diabetes Research FoundationRecruiting
-
Universidad de SantanderUniversidad Santo Tomas; Universidad Manuela Beltrán; Fundación Oftalmológica... and other collaboratorsRecruitingMild Cognitive ImpairmentColombia
-
Nemours Children's ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedType 1 Diabetes MellitusUnited States
-
University of Sao Paulo General HospitalUniversity of Campinas, BrazilUnknown
-
Sahlgrenska University HospitalVastra Gotaland RegionRecruitingMuscle Weakness | Muscle Atrophy | Hip Osteoarthritis | Arthroplasty Complications | Muscle InjurySweden
-
Iuliu Hatieganu University of Medicine and PharmacyEmergency County Hospital Cluj-NapocaCompleted
-
Florida Orthopaedic InstituteOrthopaedic Trauma AssociationCompletedTibial FracturesUnited States
-
Sorlandet Hospital HFUnknown